Negocios · 23/3/20061 min de lectura
Oral Dosage Form New Animal Drugs; Orbifloxacin
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The supplemental NADA provides for revised animal safety labeling for orbifloxacin tablets used in dogs and cats for the management of diseases associated with susceptible bacteria.